Can the radiation dose be safely reduced in the treatment of nk/T cell lymphoma?

Abstract

The aim of this study is to investigate the feasibility and safety of dose reduction in the radiotherapy of NK/T-cell lymphoma. A retrospective collection of clinical and treatment data was conducted on 41 patients. The analysis aimed to assess whether the reduction in radiation therapy dosage affected patients’ local control and survival. Among the 41 patients, all achieved complete remission after the initial treatment. With a median follow-up of 28.4 months, all except one patient demonstrated good control within the irradiated area. In the entire cohort, a total of 6 patients died and none of the deaths were caused by local tumor failure. The 3-year overall survival rate and progression-free survival rate was 83.8%, 94.4%, respectively. The incidence of long-term toxicity was low. It seems safe to reduce the prophylactic radiation dose to 45 Gy and the preliminary treatment results are satisfactory, with further reduction in side effects.

Keywords:

• NK/T cell lymphoma
• radiotherapy
• reduced dose
• side effects;

Acknowledgments

The authors thank the patients. They also thank the support from the department of lymphoma.

Ethical approval

The study was approved by Tianjin Medical University Cancer Institute and Hospital Institutional Review Board to be conducted under an abbreviated informed consent procedure and an opt-out consent principle. None of the included participants requested to be removed from the study.

Authors’ contributions

X.M.Z. designed the research; X.M.Z. and Y.L.C collected and analyzed data; X.M.Z. wrote the article; and all authors provided study materials or patients and approved the article.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Additional information

Funding

This work was supported by Tianjin Key Medical discipline(Specialty) Construction Project (TJYXZDXK-009A).